New Way to Study Pulmonary Hypertension in HFpEF

HomeCirculation ResearchVol. 133, No. 11New Way to Study Pulmonary Hypertension in HFpEF No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextNew Way to Study Pulmonary Hypertension in HFpEF Zhiyu Dai and Edward Benjamin Thorp Zhiyu DaiZhiyu Dai Correspondence to: Zhiyu Dai, PhD, Department of Internal Medicine, College of Medicine-Phoenix, University of Arizona, Phoenix, Arizona. 475 N. 5th St, Phoenix, AZ 85004, Email E-mail Address: [email protected] https://orcid.org/0000-0002-2945-7923 Division of Pulmonary, Critical Care and Sleep, Department of Internal Medicine (Z.D.), College of Medicine-Phoenix, University of Arizona, Phoenix. Translational Cardiovascular Research Center (Z.D.), College of Medicine-Phoenix, University of Arizona, Phoenix. BIO5 Institute (Z.D.), University of Arizona, Tucson. Sarver Heart Center (Z.D.) University of Arizona, Tucson (Z.D.). Search for more papers by this author and Edward Benjamin ThorpEdward Benjamin Thorp Edward B. Thorp, PhD, Feinberg School of Medicine, Northwestern University, Department of Pathology, 303 E. Chicago Ave Ward 4-116, Chicago, IL 60611, Email E-mail Address: [email protected] https://orcid.org/0000-0003-1387-7058 Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago (E.B.T.). Search for more papers by this author Originally published9 Nov 2023https://doi.org/10.1161/CIRCRESAHA.123.323753Circulation Research. 2023;133:899–901This article is a commentary on the followingMyeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEFFootnotesFor Sources of Funding and Disclosures, see page 901.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Zhiyu Dai, PhD, Department of Internal Medicine, College of Medicine-Phoenix, University of Arizona, Phoenix, Arizona. 475 N. 5th St, Phoenix, AZ 85004, Email zhiyudai@arizona.eduEdward B. Thorp, PhD, Feinberg School of Medicine, Northwestern University, Department of Pathology, 303 E. Chicago Ave Ward 4-116, Chicago, IL 60611, Email ebthorp@northwestern.eduREFERENCES1. Brittain EL, Thenappan T, Huston JH, Agrawal V, Lai Y-C, Dixon D, Ryan JJ, Lewis EF, Redfield MM, Shah SJ, et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; and Stroke Council. Elucidating the clinical implications and pathophysiology of pulmonary hypertension in heart failure with preserved ejection fraction: a call to action: a science advisory from the American heart association.Circulation. 2022; 146:e73–e88. doi: 10.1161/CIR.0000000000001079LinkGoogle Scholar2. Inampudi C, Silverman D, Simon MA, Leary PJ, Sharma K, Houston BA, Vachiéry J-L, Haddad F, Tedford RJ. Pulmonary hypertension in the context of heart failure with preserved ejection fraction.Chest. 2021; 160:2232–2246. doi: 10.1016/j.chest.2021.08.039CrossrefMedlineGoogle Scholar3. Lai Y-C, Tabima DM, Dube JJ, Hughan KS, Vanderpool RR, Goncharov DA, St. Croix CM, Garcia-Ocaña A, Goncharova EA, Tofovic SP, et al. SIRT3–AMP-Activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction.Circulation. 2016; 133:717–731. doi: 10.1161/CIRCULATIONAHA.115.018935LinkGoogle Scholar4. Meng Q, Lai Y-C, Kelly NJ, Bueno M, Baust JJ, Bachman TN, Goncharov D, Vanderpool RR, Radder JE, Hu J, et al. Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction.Am J Respir Cell Mol Biol. 2017; 56:497–505. doi: 10.1165/rcmb.2016-0177OCCrossrefMedlineGoogle Scholar5. Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay E, Omura J, Coté N, Abu-Alhayja’a R, Dumais V, Nachbar RT, et al. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease.Circ Res. 2019; 125:449–466. doi: 10.1161/CIRCRESAHA.118.314555LinkGoogle Scholar6. Agrawal V, Kropski JA, Gokey JJ, Kobeck E, Murphy M, Murray KT, Fortune NL, Moore CS, Meoli DF, Monahan K, et al. Myeloid cell derived IL1β contributes to pulmonary hypertension in HFpEF.Circulation Research. 2023; 133:885–898. doi: 10.1161/CIRCRESAHA.123.323119LinkGoogle Scholar7. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, Rich S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction.Circ Heart Fail. 2011; 4:257–265. doi: 10.1161/CIRCHEARTFAILURE.110.958801LinkGoogle Scholar8. Tong D, Schiattarella GG, Jiang N, May HI, Lavandero S, Gillette TG, Hill JA. Female sex is protective in a preclinical model of heart failure with preserved ejection fraction.Circulation. 2019; 140:1769–1771. doi: 10.1161/CIRCULATIONAHA.119.042267LinkGoogle Scholar9. Fayyaz AU, Edwards WD, Maleszewski JJ, Konik EA, DuBrock HM, Borlaug BA, Frantz RP, Jenkins SM, Redfield MM. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction.Circulation. 2018; 137:1796–1810. doi: 10.1161/CIRCULATIONAHA.117.031608LinkGoogle Scholar10. Azarbar S, Dupuis J. Lung capillary injury and repair in left heart disease: a new target for therapy?Clinical Sci (Lond). 2014; 127:65–76. doi: 10.1042/CS20130296CrossrefMedlineGoogle Scholar11. Obokata M, Kane GC, Reddy YNV, Melenovsky V, Olson TP, Jarolim P, Borlaug BA. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.Eur Heart J. 2019; 40:3707–3717. doi: 10.1093/eurheartj/ehz626CrossrefMedlineGoogle Scholar12. Pullamsetti SS, Savai R. Macrophage regulation during vascular remodeling: implications for pulmonary hypertension therapy.Am J Respir Cell Mol Biol. 2017; 56:556–558. doi: 10.1165/rcmb.2017-0033EDCrossrefMedlineGoogle Scholar13. Zawia A, Arnold ND, West L, Pickworth JA, Turton H, Iremonger J, Braithwaite AT, Cañedo J, Johnston SA, Thompson AAR, et al. Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension.Arterioscler Thromb Vasc Biol. 2021; 41:430–445. doi: 10.1161/ATVBAHA.120.314639LinkGoogle Scholar14. Assad TR, Hemnes AR, Larkin EK, Glazer AM, Xu M, Wells QS, Farber-Eger EH, Sheng Q, Shyr Y, Harrell FE, et al. Clinical and biological insights into combined post-capillary and pre-capillary pulmonary hypertension.J Am Coll Cardiol. 2016; 68:2525–2536. doi: 10.1016/j.jacc.2016.09.942CrossrefMedlineGoogle Scholar eLetters(0) eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate. Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page. Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesMyeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEFVineet Agrawal, et al. Circulation Research. 2023;133:885-898 November 10, 2023Vol 133, Issue 11 Advertisement Article Information Metrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.123.323753PMID: 37943948 Originally publishedNovember 9, 2023 KeywordsEditorialheart failurehyperlipidemiamicephenotypesPDF download Advertisement